Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

MeSH terms

• Adult
• Aged
• Alemtuzumab
• Antibodies, Monoclonal / administration & dosage
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm / administration & dosage
• Antibodies, Neoplasm / therapeutic use*
• Antineoplastic Agents / therapeutic use*
• Disease-Free Survival
• Female
• Humans
• Leukemia, Myeloid, Acute / drug therapy*
• Leukemia, Myeloid, Acute / mortality
• Male
• Middle Aged
• Myelodysplastic Syndromes / drug therapy*
• Myelodysplastic Syndromes / mortality
• Recurrence
• Stem Cell Transplantation / methods*
• Survival Analysis
• Young Adult